$TMO

Holmes Joseph R. sold $246K of TMO

Holmes Joseph R. (VP & Chief Accounting Officer) sold 420 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $584.81 ($0.25M total) on 2026-08-07.

Original reporting
SEC EDGAR · Holmes Joseph R.
Published Aug 10, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (420 shares, $584.81/share, $245,620.20 total) by a named officer, which may marginally affect sentiment but does not introduce new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no operational, financial, or regulatory catalyst in the text.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior grants, option exercises, or total insider activity, limiting inference.

Relevance 4/10Novelty 4/10Timing: Filed 2026-08-10 after-hours; reflects sale executed 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, filed on 2026-08-10.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher insider Form 4 shows VP and Chief Accounting Officer Holmes sold 420 shares at $584.81 on 2026-08-07.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited and short-lived.

Evidence & confidence

The filing is a primary-source Form 4 disclosure, but it is a single, modest-sized sale with no stated 10b5-1 plan and no accompanying company-specific news.

Market effects

No clear sector read-through; this is company-specific insider activity without broader regulatory or operational signals.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or tax/compensation liquidity rather than a bearish view, especially given the lack of any accompanying negative company event.

Key entities

  • Thermo Fisher Scientific Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Holmes Joseph R.

    VP and Chief Accounting Officer who sold 420 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QNTMMed

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$TMOMed

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

Thermo Fisher Scientific (TMO) launched the EMPAD G2 detector for advanced materials analysis, aiming to boost its Analytical Instruments segment. Shares dipped 0.8% post-announcement. The company has a $233.20B market cap, 4% earnings yield, and a track record of beating earnings estimates. The global 4D STEM market, where EMPAD G2 operates, is projected to grow at 6.6% CAGR through 2031, according to QYResearch.